Valeant Pharmaceuticals Intl Inc.: Is the Reward Worth the Risk?

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has a plan to get out of debt, but it’s going to take pristine execution.

| More on:
The Motley Fool

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you look at Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) the way I do, you likely feel equal parts greed and terror. On one hand, you see a stock that is trading at under $16 a share, when a year and a half ago, it was trading over $335 a share, so you dream of it returning to those sorts of prices. But, on the other hand, you’ve got a company carrying nearly US$30 billion in debt; if the company were to go into bankruptcy, investors would be left with nothing.

So, what should we do? Is the potential reward worth all the risk associated with Valeant?

It all depends on how the company does managing that debt going forward. Valeant owes US$2.6 billion in 2018, US$1.1 billion in 2019, US$7.7 billion in 2020, and US$3.2 billion in 2021 — not to mention the US$13.3 billion due in years following. In the next four years, Valeant has to pay US$14.6 billion, which is a huge mountain of debt for any company to overcome, but it’s especially concerning for Valeant because its revenue is dropping.

In 2015, Valeant had US$10.4 billion in revenue, but by the end of 2016, revenue dropped to US$9.6 billion. And, as is expected, the company had a significant net income loss of US$2.4 billion. But cash flow is what matters right now with regard to ensuring that its debt payments can be made and, for the most part, this is relatively constant. In 2015, Valeant had US$2.257 billion in cash flow; in 2016, cash flow dropped 8% to $2.087 billion. No one likes to see that happen, but there were also some asset sales that contributed to a reduction in total sales.

The question is, Can it manage that debt? The company paid down US$1.1 billion of its debt earlier this week thanks to some asset sales announced back in January. But, just as important, Valeant is looking to refinance some of that debt to hopefully make it more manageable. Remember, Valeant owes US$14.6 billion over the next four years. That’s a lot and doesn’t give the company much time to work on its turnaround strategy. Growth is possible at Valeant, but not with so much debt coming due in a few years’ time.

The company is hoping to refinance all of its loans that are due between now and 2022 and push them later. There are positives and negatives to this strategy. On the one hand, pushing debt out tends to make it more expensive, so theoretically, more interest will be charged (and interest rates are going up). On the other hand, this strategy will give the company some wiggle room, so it can execute its business plan. While there is no guarantee that this refinance will occur, I think it’s a generally positive step for the company.

You’re likely scratching your head and questioning whether you should buy Valeant or not. The answer is both yes and no. Valeant owns plenty of incredible assets that, when they reach scale, could generate growth. But it has a tonne of debt, which will hold it back until it is paid off. If you’re going to invest here, understand it’s a speculative trade. You could make a lot of money, but you could lose it all in liquidation. Tread carefully.

Should you invest $1,000 in Bausch Health Companies right now?

Before you buy stock in Bausch Health Companies, consider this:

The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and Bausch Health Companies wasn’t one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years.

Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $20,697.16!*

Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 29 percentage points since 2013*.

See the Top Stocks * Returns as of 3/20/25

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Jacob Donnelly has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

Confidently Navigate Market Volatility: Claim Your Free Report!

Feeling uneasy about the ups and downs of the stock market lately? You’re not alone. At The Motley Fool Canada, we get it — and we’re here to help. We’ve crafted an essential guide designed to help you through these uncertain times: "5-Step Checklist: How to Prepare Your Portfolio for Volatility."

Don't miss out on this opportunity for peace of mind. Just click below to learn how to receive your complimentary report today!

Get Our Free Report Today

More on Investing

Stocks for Beginners

Dip Buyers Could Win Big: The Best Canadian Stocks to Buy Now

These two growth stocks have taken hits recently, but their fundamentals remain strong, and their growth prospects are intact.

Read more »

A bull and bear face off.
Stock Market

Bear Market Bargains Emerge as Recession Stocks Return

If you want a deal, then go to the best stocks during a recession market dip.

Read more »

Canadian Red maple leaves seamless wallpaper pattern
Dividend Stocks

5 Canadian Dividend Stocks to Buy and Hold for the Next 20 Years

These Canadian stocks have paid dividends for decades, making them reliable investments to generate regular passive income.

Read more »

An investor uses a tablet
Stocks for Beginners

The Smartest Canadian Stock to Buy With $250 Right Now

Are you looking for the smartest Canadian stock to buy right now? Consider this gem and avoid market volatility.

Read more »

Dividend Stocks

3 Canadian REIT Stocks to Buy and Hold for the Next Quarter-Century

These three Canadian REITs trade cheaply and are highly reliable, making them some of the best stocks you can buy…

Read more »

Electricity transmission towers with orange glowing wires against night sky
Investing

Fortis Just Might Be the Best Canadian Dividend Stock to Buy in April

Let's dive into a few reasons why Canadian utility giant Fortis (TSX:FTS) still looks like a screaming buy heading into…

Read more »

A train passes Morant's curve in Banff National Park in the Canadian Rockies.
Dividend Stocks

1 Practically Perfect Canadian Stock Down 24% to Buy Now and Hold for Life!

CNR stock is a top Canadian stock for investors, especially with shares down on the TSX today.

Read more »

a man relaxes with his feet on a pile of books
Investing

Got $7,000? How I’d Spread It Across 5 Blue-Chip Stocks for an Investing Foundation

Spreading $7,000 across these five blue-chip stocks provides a solid foundation for long-term financial success.

Read more »